{"id": "article-25196_0", "title": "Mitomycin -- Continuing Education Activity", "content": "Mitomycin is a medication used in the treatment of anal carcinoma, bladder carcinoma, breast carcinoma, head and neck malignancies, and some other gastrointestinal carcinomas. It is in the antineoplastic antibiotic class of medications. This activity reviews the mechanism of action, adverse event profile, indication, and contraindication for mitomycin as a valuable agent in managing gastrointestinal and urogenital cancers.", "contents": "Mitomycin -- Continuing Education Activity. Mitomycin is a medication used in the treatment of anal carcinoma, bladder carcinoma, breast carcinoma, head and neck malignancies, and some other gastrointestinal carcinomas. It is in the antineoplastic antibiotic class of medications. This activity reviews the mechanism of action, adverse event profile, indication, and contraindication for mitomycin as a valuable agent in managing gastrointestinal and urogenital cancers."}
{"id": "article-25196_1", "title": "Mitomycin -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of mitomycin. Describe the contraindications of mitomycin. Review the adverse effects/toxicity of mitomycin. Outline some interprofessional team strategies for improving care coordination and communication to advance mitomycin and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Mitomycin -- Continuing Education Activity. Objectives: Identify the mechanism of action of mitomycin. Describe the contraindications of mitomycin. Review the adverse effects/toxicity of mitomycin. Outline some interprofessional team strategies for improving care coordination and communication to advance mitomycin and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-25196_2", "title": "Mitomycin -- Indications", "content": "Mitomycin is an antibiotic medication approved by the Food and Drug Administration (FDA) for use\u00a0in the systemic therapy of\u00a0metastatic\u00a0adenocarcinoma of the stomach or pancreas in combination with other drugs. [1] Mitomycin is also indicated for the treatment of bladder cancer, with maintenance doses of mitomycin proving effective for decreasing the tumor recurrence rate of low and intermediate-risk tumors. [2]", "contents": "Mitomycin -- Indications. Mitomycin is an antibiotic medication approved by the Food and Drug Administration (FDA) for use\u00a0in the systemic therapy of\u00a0metastatic\u00a0adenocarcinoma of the stomach or pancreas in combination with other drugs. [1] Mitomycin is also indicated for the treatment of bladder cancer, with maintenance doses of mitomycin proving effective for decreasing the tumor recurrence rate of low and intermediate-risk tumors. [2]"}
{"id": "article-25196_3", "title": "Mitomycin -- Indications", "content": "This medication is also indicated as a potential palliative treatment, especially when other treatments have failed. It also has approval for use as an adjunct to ab-externo glaucoma surgery. [3] Due to raised intraocular pressure in the development of glaucoma, mitomycin is used during surgery to reduce postoperative scarring following a trabeculectomy or glaucoma drainage surgery. [4] [3] However, its use in hepatic artery chemoembolization is yet to be approved by the FDA.", "contents": "Mitomycin -- Indications. This medication is also indicated as a potential palliative treatment, especially when other treatments have failed. It also has approval for use as an adjunct to ab-externo glaucoma surgery. [3] Due to raised intraocular pressure in the development of glaucoma, mitomycin is used during surgery to reduce postoperative scarring following a trabeculectomy or glaucoma drainage surgery. [4] [3] However, its use in hepatic artery chemoembolization is yet to be approved by the FDA."}
{"id": "article-25196_4", "title": "Mitomycin -- Mechanism of Action", "content": "Mitomycin is an antibiotic that is isolated from the broth of Streptomyces caespitosus. This drug has demonstrated antitumor activity. [5] [6] Mitomycin belongs to a group of\u00a0alkylating agents that work by\u00a0cross-linking the complementary strands found in DNA with absolute specificity and high efficiency for the CpG sequence. [3]", "contents": "Mitomycin -- Mechanism of Action. Mitomycin is an antibiotic that is isolated from the broth of Streptomyces caespitosus. This drug has demonstrated antitumor activity. [5] [6] Mitomycin belongs to a group of\u00a0alkylating agents that work by\u00a0cross-linking the complementary strands found in DNA with absolute specificity and high efficiency for the CpG sequence. [3]"}
{"id": "article-25196_5", "title": "Mitomycin -- Mechanism of Action", "content": "Once activated by a reduction cascade, a series of spontaneous transformations cause mitomycin to attack DNA twice, resulting in cross-linking of strands of DNA double helix, thereby inhibiting DNA synthesis. Mitomycin is non-specific for a particular cell cycle phase but can exert its\u00a0maximum effect in both the late G as well as the early S-phases. [6]", "contents": "Mitomycin -- Mechanism of Action. Once activated by a reduction cascade, a series of spontaneous transformations cause mitomycin to attack DNA twice, resulting in cross-linking of strands of DNA double helix, thereby inhibiting DNA synthesis. Mitomycin is non-specific for a particular cell cycle phase but can exert its\u00a0maximum effect in both the late G as well as the early S-phases. [6]"}
{"id": "article-25196_6", "title": "Mitomycin -- Mechanism of Action", "content": "It also suppresses RNA and protein synthesis at higher concentrations, hence being useful against some bacteria, spirochetes, and viruses. Lending to its toxic profile,\u00a0mitomycin has a limited role as an antibiotic. [6] Mitomycin also causes chromosomal breaks, thus leading to shortened strands of DNA, which eventually leads to chromosomal damage; this property renders\u00a0mitomycin a potent carcinogen and teratogen. [3] In glaucoma surgery, the antifibrotic property of mitomycin prevents tissue scarring\u00a0when surgeons create a surgical ocular flap to relieve excess fluid buildup. [4]", "contents": "Mitomycin -- Mechanism of Action. It also suppresses RNA and protein synthesis at higher concentrations, hence being useful against some bacteria, spirochetes, and viruses. Lending to its toxic profile,\u00a0mitomycin has a limited role as an antibiotic. [6] Mitomycin also causes chromosomal breaks, thus leading to shortened strands of DNA, which eventually leads to chromosomal damage; this property renders\u00a0mitomycin a potent carcinogen and teratogen. [3] In glaucoma surgery, the antifibrotic property of mitomycin prevents tissue scarring\u00a0when surgeons create a surgical ocular flap to relieve excess fluid buildup. [4]"}
{"id": "article-25196_7", "title": "Mitomycin -- Administration", "content": "Mitomycin administration is via the intravenous and intravesical routes. Subcutaneous or intramuscular administration is not advised or recommended. Close monitoring\u00a0during\u00a0intravenous infusions is advised due to the high likelihood of extravasation. Signs of extravasation include poor blood return, pain, and swelling. [7]", "contents": "Mitomycin -- Administration. Mitomycin administration is via the intravenous and intravesical routes. Subcutaneous or intramuscular administration is not advised or recommended. Close monitoring\u00a0during\u00a0intravenous infusions is advised due to the high likelihood of extravasation. Signs of extravasation include poor blood return, pain, and swelling. [7]"}
{"id": "article-25196_8", "title": "Mitomycin -- Administration", "content": "Extreme caution is necessary to prevent extravasation as the drug is known to cause irritation, skin ulceration, and cellulitis. Given the cytotoxic nature of mitomycin, precautions and procedures for handling, reconstitution, and disposal require strict adherence. It can be diluted up to a concentration of 40 micrograms per milliliter at room temperature\u00a0in 5% dextrose, 0.9% sodium chloride, or sodium lactate injection. These solutions are stable and\u00a0should be used within 4 hours, 48 hours, or 24 hours, respectively.", "contents": "Mitomycin -- Administration. Extreme caution is necessary to prevent extravasation as the drug is known to cause irritation, skin ulceration, and cellulitis. Given the cytotoxic nature of mitomycin, precautions and procedures for handling, reconstitution, and disposal require strict adherence. It can be diluted up to a concentration of 40 micrograms per milliliter at room temperature\u00a0in 5% dextrose, 0.9% sodium chloride, or sodium lactate injection. These solutions are stable and\u00a0should be used within 4 hours, 48 hours, or 24 hours, respectively."}
{"id": "article-25196_9", "title": "Mitomycin -- Administration -- Dosing for Approved Indications", "content": "Refractory stomach or pancreatic cancer: 20 mg/m^2/doise IV on the first day of a 42- or 56-day cycle as part of a multi-drug chemotherapy regimen. If the patient has a serum creatinine greater than 1.7, use of this drug should be avoided. In ophthalmology, topical administration is the only established route of administration. [3] [4]", "contents": "Mitomycin -- Administration -- Dosing for Approved Indications. Refractory stomach or pancreatic cancer: 20 mg/m^2/doise IV on the first day of a 42- or 56-day cycle as part of a multi-drug chemotherapy regimen. If the patient has a serum creatinine greater than 1.7, use of this drug should be avoided. In ophthalmology, topical administration is the only established route of administration. [3] [4]"}
{"id": "article-25196_10", "title": "Mitomycin -- Adverse Effects", "content": "Bone marrow toxicity is the most commonly reported adverse effect, occurring in most patients\u00a0treated with mitomycin in one study. It produces cumulative myelosuppression. Thrombocytopenia and possibly leukopenia may occur anytime within the first two months\u00a0after beginning therapy,\u00a0with an average\u00a0duration of one month. [8] The recovery time after the termination of therapy was\u00a0about ten weeks. About 25%\u00a0of the leukopenic or thrombocytopenic episodes were permanent and did not return to baseline levels. As these patients are already immunocompromised, extreme caution is necessary to ensure further bone marrow suppression does not contribute to overwhelming subsequent infections.", "contents": "Mitomycin -- Adverse Effects. Bone marrow toxicity is the most commonly reported adverse effect, occurring in most patients\u00a0treated with mitomycin in one study. It produces cumulative myelosuppression. Thrombocytopenia and possibly leukopenia may occur anytime within the first two months\u00a0after beginning therapy,\u00a0with an average\u00a0duration of one month. [8] The recovery time after the termination of therapy was\u00a0about ten weeks. About 25%\u00a0of the leukopenic or thrombocytopenic episodes were permanent and did not return to baseline levels. As these patients are already immunocompromised, extreme caution is necessary to ensure further bone marrow suppression does not contribute to overwhelming subsequent infections."}
{"id": "article-25196_11", "title": "Mitomycin -- Adverse Effects", "content": "Hemolytic uremic syndrome (HUS)\u00a0has been observed in patients receiving systemic medication, with an incidence of <15%. [1]  Patients presented with microangiopathic hemolytic anemia with fragmented red blood cells on peripheral blood smears. Patients with HUS also suffer the common and well-known side effects of the syndrome, including thrombocytopenia (\u2264100,000/mm) and renal failure (serum creatinine \u22651.6 mg/dL), which is irreversible. The use of\u00a0blood product transfusions has correlated with exacerbation of the HUS symptoms. There is a high mortality rate of\u00a052% associated with this syndrome. [9]", "contents": "Mitomycin -- Adverse Effects. Hemolytic uremic syndrome (HUS)\u00a0has been observed in patients receiving systemic medication, with an incidence of <15%. [1]  Patients presented with microangiopathic hemolytic anemia with fragmented red blood cells on peripheral blood smears. Patients with HUS also suffer the common and well-known side effects of the syndrome, including thrombocytopenia (\u2264100,000/mm) and renal failure (serum creatinine \u22651.6 mg/dL), which is irreversible. The use of\u00a0blood product transfusions has correlated with exacerbation of the HUS symptoms. There is a high mortality rate of\u00a052% associated with this syndrome. [9]"}
{"id": "article-25196_12", "title": "Mitomycin -- Adverse Effects", "content": "In another study, nausea, fever, vomiting, and anorexia occurred in up to 14% of people taking mitomycin. Alopecia and stomatitis occurred in up to 4% of individuals. Roughly\u00a02% of the patients showed\u00a0a statistically significant rise in\u00a0creatinine. However, there was no correlation between the dose given or duration of therapy with the degree of renal impairment. [10]", "contents": "Mitomycin -- Adverse Effects. In another study, nausea, fever, vomiting, and anorexia occurred in up to 14% of people taking mitomycin. Alopecia and stomatitis occurred in up to 4% of individuals. Roughly\u00a02% of the patients showed\u00a0a statistically significant rise in\u00a0creatinine. However, there was no correlation between the dose given or duration of therapy with the degree of renal impairment. [10]"}
{"id": "article-25196_13", "title": "Mitomycin -- Adverse Effects", "content": "Pulmonary toxicity has been infrequently reported, with patients\u00a0presenting with\u00a0dyspnea, nonproductive cough, and pulmonary infiltrates on radiologic imaging. [11] Vinca alkaloids, a common class of chemotherapeutic agents, also showed\u00a0severe or life-threatening dyspnea and bronchospasm within minutes to hours of mitomycin administration. [10] Adult respiratory distress syndrome has also occurred\u00a0in patients receiving mitomycin with other medications. [12]", "contents": "Mitomycin -- Adverse Effects. Pulmonary toxicity has been infrequently reported, with patients\u00a0presenting with\u00a0dyspnea, nonproductive cough, and pulmonary infiltrates on radiologic imaging. [11] Vinca alkaloids, a common class of chemotherapeutic agents, also showed\u00a0severe or life-threatening dyspnea and bronchospasm within minutes to hours of mitomycin administration. [10] Adult respiratory distress syndrome has also occurred\u00a0in patients receiving mitomycin with other medications. [12]"}
{"id": "article-25196_14", "title": "Mitomycin -- Adverse Effects", "content": "The most frequent adverse events\u00a0with ocular administration of mitomycin occur locally and include blebitis, hypotony maculopathy, hypotony, endophthalmitis, cataract development, vascular reactions, and corneal reactions. [4]", "contents": "Mitomycin -- Adverse Effects. The most frequent adverse events\u00a0with ocular administration of mitomycin occur locally and include blebitis, hypotony maculopathy, hypotony, endophthalmitis, cataract development, vascular reactions, and corneal reactions. [4]"}
{"id": "article-25196_15", "title": "Mitomycin -- Contraindications", "content": "Mitomycin is generally avoided and somewhat contraindicated in patients with a history of reactions\u00a0to the drug, whether a hypersensitivity reaction or an idiosyncratic reaction. Its use is\u00a0not recommended for patients with a high serum creatinine >1.7 mg/dL or creatinine clearance <30 mL/min. Other contraindications include\u00a0coagulopathy, thrombocytopenia, or any bleeding diathesis. [8] Mitomycin\u00a0should be avoided\u00a0in patients with severe immunosuppression due to bone marrow suppression, including leukopenia and thrombocytopenia.", "contents": "Mitomycin -- Contraindications. Mitomycin is generally avoided and somewhat contraindicated in patients with a history of reactions\u00a0to the drug, whether a hypersensitivity reaction or an idiosyncratic reaction. Its use is\u00a0not recommended for patients with a high serum creatinine >1.7 mg/dL or creatinine clearance <30 mL/min. Other contraindications include\u00a0coagulopathy, thrombocytopenia, or any bleeding diathesis. [8] Mitomycin\u00a0should be avoided\u00a0in patients with severe immunosuppression due to bone marrow suppression, including leukopenia and thrombocytopenia."}
{"id": "article-25196_16", "title": "Mitomycin -- Monitoring", "content": "Patients receiving treatment with this medication should\u00a0be observed during and after therapy. HUS may occur at any point during therapy, with signs such as anemia, thrombocytopenia, and renal failure,\u00a0especially when\u00a0patients receive doses exceeding 60 mg. Fragmented red blood cells may also be present on peripheral smear. [1] [8]", "contents": "Mitomycin -- Monitoring. Patients receiving treatment with this medication should\u00a0be observed during and after therapy. HUS may occur at any point during therapy, with signs such as anemia, thrombocytopenia, and renal failure,\u00a0especially when\u00a0patients receive doses exceeding 60 mg. Fragmented red blood cells may also be present on peripheral smear. [1] [8]"}
{"id": "article-25196_17", "title": "Mitomycin -- Monitoring", "content": "The use of mitomycin in pregnant women remains unestablished; therefore, it is not recommended from a safety standpoint. Parenterally-administered mitomycin can cause fetal issues if given during pregnancy; it is classified into category D by the FDA. Breastfeeding is not recommended and is to\u00a0be discontinued when receiving mitomycin therapy. [13]", "contents": "Mitomycin -- Monitoring. The use of mitomycin in pregnant women remains unestablished; therefore, it is not recommended from a safety standpoint. Parenterally-administered mitomycin can cause fetal issues if given during pregnancy; it is classified into category D by the FDA. Breastfeeding is not recommended and is to\u00a0be discontinued when receiving mitomycin therapy. [13]"}
{"id": "article-25196_18", "title": "Mitomycin -- Toxicity", "content": "Pulmonary toxicity is a rare but well-documented adverse effect of mitomycin C. In one trial at the Mayo Clinic, despite pre-medication with the use of corticosteroids, pulmonary toxicity occurred, with changes in diffusing lung capacity of 9 and PaO2 of 49 mm Hg. A significant number of patients who had bronchoscopies had changes noted on pulmonary histology consistent with lung injury. [12]", "contents": "Mitomycin -- Toxicity. Pulmonary toxicity is a rare but well-documented adverse effect of mitomycin C. In one trial at the Mayo Clinic, despite pre-medication with the use of corticosteroids, pulmonary toxicity occurred, with changes in diffusing lung capacity of 9 and PaO2 of 49 mm Hg. A significant number of patients who had bronchoscopies had changes noted on pulmonary histology consistent with lung injury. [12]"}
{"id": "article-25196_19", "title": "Mitomycin -- Toxicity", "content": "Despite initial responses to corticosteroids, 40% of patients still experienced progressive pulmonary insufficiency despite very high corticosteroid doses. Attention must focus on the chronic and progressive phase of lung toxicity associated with mitomycin C, as this event is a largely underestimated complication of the treatment regimen. [12] [14]", "contents": "Mitomycin -- Toxicity. Despite initial responses to corticosteroids, 40% of patients still experienced progressive pulmonary insufficiency despite very high corticosteroid doses. Attention must focus on the chronic and progressive phase of lung toxicity associated with mitomycin C, as this event is a largely underestimated complication of the treatment regimen. [12] [14]"}
{"id": "article-25196_20", "title": "Mitomycin -- Enhancing Healthcare Team Outcomes", "content": "Mitomycin use requires a specialized care setting. Management of therapy and potential adverse effects is only possible\u00a0with adequate facilities and\u00a0a specialized\u00a0interprofessional\u00a0team.\u00a0Myelosuppression may prove\u00a0severe and can necessitate\u00a0dose reductions. Therefore, mitomycin\u00a0requires an experienced healthcare professional who is\u00a0knowledgeable in the discipline of chemotherapy. It also requires close cooperation between primary care physicians, oncologists, hematologists, and pharmacists to enhance patient care, improve outcomes and quality of life.", "contents": "Mitomycin -- Enhancing Healthcare Team Outcomes. Mitomycin use requires a specialized care setting. Management of therapy and potential adverse effects is only possible\u00a0with adequate facilities and\u00a0a specialized\u00a0interprofessional\u00a0team.\u00a0Myelosuppression may prove\u00a0severe and can necessitate\u00a0dose reductions. Therefore, mitomycin\u00a0requires an experienced healthcare professional who is\u00a0knowledgeable in the discipline of chemotherapy. It also requires close cooperation between primary care physicians, oncologists, hematologists, and pharmacists to enhance patient care, improve outcomes and quality of life."}
{"id": "article-25196_21", "title": "Mitomycin -- Enhancing Healthcare Team Outcomes", "content": "Any practitioner who must give an\u00a0intravesical treatment requires appropriate training and assessment. This will apply to all MDs, DOs, NPs, and PAs attending to the patient. They should demonstrate a focused understanding of\u00a0underlying malignancy,\u00a0associated health care concerns, and matters of safety in\u00a0the handling of these drugs, as well as demonstrating clinical competence related to the drug. Nurses attending the patient should also have specialty oncology experience. An oncological board-certified pharmacist must also monitor dosing and consult with the rest of the team regarding adverse events and potential alternative therapy. Interprofessional teamwork, collaboration, and communication are crucial to successful mitomycin therapy. [Level 5] Both patients and the practitioner must be educated about mitomycin, its administration, and its adverse effects.", "contents": "Mitomycin -- Enhancing Healthcare Team Outcomes. Any practitioner who must give an\u00a0intravesical treatment requires appropriate training and assessment. This will apply to all MDs, DOs, NPs, and PAs attending to the patient. They should demonstrate a focused understanding of\u00a0underlying malignancy,\u00a0associated health care concerns, and matters of safety in\u00a0the handling of these drugs, as well as demonstrating clinical competence related to the drug. Nurses attending the patient should also have specialty oncology experience. An oncological board-certified pharmacist must also monitor dosing and consult with the rest of the team regarding adverse events and potential alternative therapy. Interprofessional teamwork, collaboration, and communication are crucial to successful mitomycin therapy. [Level 5] Both patients and the practitioner must be educated about mitomycin, its administration, and its adverse effects."}
{"id": "article-25196_22", "title": "Mitomycin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Mitomycin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}